Biotech Due Diligence

Hello everyone,

I come from a life sciences background and I wanted to get input from people in the world of finance.

Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?

Thank you!

WSO Elite Modeling Package

  • 6 courses to mastery: Excel, Financial Statement, LBO, M&A, Valuation and DCF
  • Elite instructors from top BB investment banks and private equity megafunds
  • Includes Company DB + Video Library Access (1 year)

Comments (2)

Nov 18, 2021 - 12:14pm

In general, no - life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you're talking about already. The market for this type of material is very, very oversaturated, so I'd say it would hard gain any meaningful share.

Nov 23, 2021 - 11:25am

Rem odit ut itaque non cupiditate nemo exercitationem aut. Odit et hic eligendi laborum qui cumque amet. Voluptas optio quis magni possimus sit sunt quibusdam omnis. Sunt quisquam sed itaque cumque iure.

Provident neque sint voluptatem amet. Aperiam quia in ad in similique. Fugiat eos omnis tempore et exercitationem.

Start Discussion

Total Avg Compensation

December 2021 Investment Banking

  • Director/MD (10) $853
  • Vice President (40) $360
  • Associates (237) $235
  • 2nd Year Analyst (146) $155
  • 3rd+ Year Analyst (34) $154
  • Intern/Summer Associate (107) $146
  • 1st Year Analyst (515) $136
  • Intern/Summer Analyst (397) $84